Addex Therapeutics Ltd is to receive $2.8 million in new research funding as part of an extended agreement with Indivior Plc, a specialty pharma company developing treatments for addiction disorders. The two companies have been working together since early 2018 and the amended agreement will now run until 30 June 2021.
